Increased binding of fibrinogen to glycoprotein IIIa-Proline33 (HPA-1b, Pl(A2), Zwb) positive platelets in patients with cardiovascular disease

European Heart Journal

Volumn 20, Issue 10, 1999, Pages 742-747

  Goodall, A H ^a,e   Curzen, N ^b   Panesar, M ^b   Hurd, C ^c   Knight, C J ^b   Ouwehand, W H ^c,d   Fox, K M ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Fibrinogen; Flow cytometry; Glycoprotein IIb IIIa; Platelets; Polymorphism

Indexed keywords

ADENOSINE DIPHOSPHATE; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IIIA; THROMBIN;

ADULT; AGED; ALLELE; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FLOW CYTOMETRY; HOMOZYGOTE; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE; THROMBOCYTE VOLUME;

AGED; ALLELES; ANGINA PECTORIS; BLOOD PLATELETS; DNA; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC; PROLINE; PROTEIN BINDING;

EID: 0033135674     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1203     Document Type: Article

References (34)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (part 1). N Engl J Med 1992; 326: 242-50.
2. Coller BS. Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med 1992; 43: 171-80.
3. Antiplatelet trialists collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
4. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
5. Trip MD, Cats VM, van Capelle FJL, Vreeken J. Platelet hyper-reactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-54.
6. Tschoepe D, Schultheiss HP, Kolarov P et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
7. Lefkowitz RJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
8. Simoons ML, de Boer MJ, van den Brand MJBM et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
9. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-6 1.
10. Kleiman NS, Ohman EM, Califf RM et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results from the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-9.
11. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43.
12. Newman PJ, Valentin N. Human platelet alloantigens: Recent findings, new perspectives. Thromb Haemost 1995; 74: 234-9.
13. A2, are associated with a leucine33/ proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-81.
14. Simsek S, Faber NM, Bleeker PM et al. Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis. Blood 1993; 81: 835-40.
15. Weiss EJ, Bray PF, Tayback M et al. A polymorphism of a platelet glycoprotein receptor is an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
16. Goldschmidt-Clermont PJ, Shear WS, Schwartberg J, Varga CF, Bray PF. Clues to the death of an olympic champion. Lancet 1996; 347: 1833.
17. Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen in normal subjects and patients with activated platelets. Thromb Haemost 1993; 70: 659-66.
18. Knight CJ, Panesar M, Wilson DJ et al. Different effects of calcium antagonists, nitrates, and β-blockers on platelet function. Circulation 1997; 95: 125-32.
19. Cavanagh G, Dunn AN, Chapman CE, Metcalfe P. HPA genotyping by PCR sequence specific priming (PCR-SSP): A streamlined method for rapid routine investigations. Trans Med 1997; 7: 41-5.
20. Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF. Gene frequencies of the five major human platelet antigens in african american, white and korean populations. Transfusion 1995; 35: 863-7.
21. Haas TA, Plow EF. Integrin ligand interactions:- A year in review. Curr Opin Cell Biol 1994; 6: 656-62.
22. A1 is not associated with inhibition of fibrinogen binding to platelet GPIIb/IIIa. Am J Clin Pathol 1995; 103: 535-641.
23. Shattil SJ. Function and regulation of the β3 integrins in hemostasis and vascular biology. Thromb Haemost 1995; 74: 149-55.
24. Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller N, Goodall AH. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of a-granules or lysosomes from, human platelets. Clin Sci 1994; 87: 575-80.
25. Samani NJ, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res 1997; 33: 693-7.
26. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
27. A2) of the glycoprotein IIIa (PGIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemostas 1997; 77: 1179-81.
28. Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996; 348: 1309-10.
29. A polymorphism and myocardial infarction. N Engl J Med 1996; 335: 1071-2.
30. Carter AM, Ossei-Gerning N, Grant PJ. Platelet glycoprotein IIIa Pl polymorphism in young men with myocardial infarction. Lancet 1996; 348: 485-6.
31. A polymorphism and myocardial infarction. N Engl J Med 1996; 335: 1072-3.
32. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiler AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997; 350: 1217-19.
33. A2 polymorphism. Circulation 1997; 96: I-412.
34. Schomig A, Neuman FJ, Kastrati A et al. A randomised comparison of antiplatelet therapy after the placement of coronary stents. N Engl J Med 1996; 334: 1084-9.